PDCD1 and small cell lung carcinoma: This meta‐analysis of first‐line therapies by patients with ES‐SCLC did not include PD‐1 inhibitors because the literature search was done up until December 2019, when there were no phase II or III clinical trials on PD‐1 inhibitors for first‐line therapies for patients with ES‐SCLC.